Silver Book Fact

MRSA infections increase in older patients

In 2008, 75% of healthcare-associated invasive MRSA infections occurred in patients older than 50, with 46% in patients older than 65%.

Kallen, Alexander J., Yi Mu, Sandra Bulens, Arthur Reingold, Susan Petit, Ken Gershman, Susan M. Ray, Lee H. Harrison, Ruth Lynfield, Ghinwa Dumyati, John M. Townes, William Schaffner, Priti R. Patel, Scott K. Fridkin; for the Active Bacterial Core surveillance (ABCs) MRSA Investigators of the Emerging Infections Program. Healthcare-Associated Invasive MRSA Infections, 2005-2008. JAMA. 2010; 304(6): 641-7. http://jama.jamanetwork.com/article.aspx?articleid=186385

Reference

Title
Healthcare-Associated Invasive MRSA Infections, 2005-2008
Publication
JAMA
Publication Date
2010
Authors
Kallen, Alexander J., Yi Mu, Sandra Bulens, Arthur Reingold, Susan Petit, Ken Gershman, Susan M. Ray, Lee H. Harrison, Ruth Lynfield, Ghinwa Dumyati, John M. Townes, William Schaffner, Priti R. Patel, Scott K. Fridkin; for the Active Bacterial Core surveillance (ABCs) MRSA Investigators of the Emerging Infections Program
Volume & Issue
Volume 304, Issue 6
Pages
641-7
URL
Read Full Resource

Categories

  • Cost of Disease
  • Age - A Major Risk Factor

Related Facts

  • Sepsis accounts for nearly 1/2 of ICU expenditures
    Infection and related sepsis/septicemia account for 40% of all ICU expenditures.  
  • Majority of physicians treated patient with at least 1 drug-resistant infection
    63% of surveyed infectious disease physicians treated a patient with at least one drug-resistant infection in 2011. 56% believed those infections to be on the rise.  
  • Most common principal diagnoses for hospitalized patients with HAIs
    The most common principal diagnoses for hospitalized patients with HAIs are: Septicemia 11.8% Adult respiratory failure 5.9% Complications from surgical or medical care 4.1%  
  • Sepsis hospitalization rate increases with age
    The rate of hospitalization for sepsis/septicemia in 2008 was around 30 times higher for patients ages 85 and older, than for those under the age of 65.  
  • Drug-resistant MRSA expensive to treat
    As an example, the median treatment cost for drug-resistant MRSA patients over a 6-month period was 118% higher than the cost of treating drug-susceptible MRSA strains.